- •Clinical and radiological stability for ≥2 years can be a milestone to stop DMT.
- •We utilized MRI activity as an inclusion criteria and also as an outcome measure.
- •The impact of stopping DMT may differ based on the age at the discontinuation.
- •Younger patients may have a higher risk of new disease activities after stopping DMT.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.BMC Neurol. 2011; 11: 144
- Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years.Mult. Scler. Relat. Disord. 2014; 3: 186-193
- Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta.Ann. Neurol. 2013; 73: 95-103
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy.N. Engl. J. Med. 2012; 366: 1870-1880
- Discontinuation of disease-modifying therapies in multiple sclerosis – clinical outcome and prognostic factors.Mult. Scler. 2017; 23: 1241-1248
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Neurol. 2014; 13: 545-556
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.Lancet. 2012; 380: 1819-1828
- Switching therapies in multiple sclerosis.CNS Drugs. 2013; 27: 239-247
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.Eur. J. Neurol. 2011; 18: 69-77
- A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study.Autoimmun. Rev. 2006; 5: 532-536
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.N. Engl. J. Med. 2012; 367: 1098-1107
- Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial.Neurology. 2012; 78: 1315-1322
- Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group.Neurology. 1995; 45: 1277-1285
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.N. Engl. J. Med. 2008; 358: 676-688
- The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.Neurology. 2016; 87: 978-987
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 387-401
- Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.J. Neurol. Neurosurg. Psychiatry. 2016; 87: 1133-1137
- Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.J. Neurol. Sci. 2018; 391: 72-76
- Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Cochrane Database Syst. Rev. 2014; CD009333
- Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.Patient Prefer. Adherence. 2017; 11: 1093-1101
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.Lancet Neurol. 2008; 7: 903-914
- Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.Mult. Scler. 2005; 11: 46-50
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med. 2006; 354: 899-910
- New diagnostic criteria for multiple sclerosis: guidelines for research protocols.Ann. Neurol. 1983; 13: 227-231
- Multiple sclerosis.N. Engl. J. Med. 2018; 378: 169-180
- PML in a patient with lymphocytopenia treated with dimethyl fumarate.N. Engl. J. Med. 2015; 372: 1476-1478
- Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.JAMA. 2012; 308: 247-256
- Stopping immunomodulatory medications in MS: frequency, reasons and consequences.Mult. Scler. Relat. Disord. 2015; 4: 437-443
- Predicting the profile of increasing disability in multiple sclerosis.Mult. Scler. 2018; (1352458518790397 (Epub-ahead of print))
- Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.J. Neurol. Sci. 2005; 239: 95-99
- Relapses in multiple sclerosis are age- and time-dependent.J. Neurol. Neurosurg. Psychiatr. 2008; 79: 1368-1374
- MRI in the diagnosis and monitoring of multiple sclerosis: an update.Clin. Neuroradiol. 2015; 25: 157-165